Quality & complianceOfficial

Gabapentin Viatris 600 mg tablets face Danish supply disruption linked to production problems

🇩🇰 DKMA · Fri 23 Oct 2026

The Danish Medicines Agency reports current supply problems for Viatris ApS's gabapentin 600 mg film-coated tablets, with disruption expected from mid-June to mid-November 2026.

The Danish Medicines Agency (DKMA) has published a supply notice for Gabapentin "Viatris" 600 mg film-coated tablets, saying there are current problems with the supply of the product from Viatris ApS. The notice is dated 23 October 2026.

DKMA gives production problems as the cause. The expected period of disruption runs from mid-June to mid-November 2026, so the notice was issued well into the stated window.

The product is identified as gabapentin, ATC code N02BF01, in the 600 mg film-coated tablet strength. The notice names Viatris ApS as the company concerned.

The agency does not describe the nature of the production problems, and it does not name alternative products or give guidance on managing patients. It says questions about the current status should be put to the company. The notice sits in DKMA's section for announcements on the supply of medicines.

What it means for your team

  • Supply-chain and pharmacy teams in Denmark should check current stock of Gabapentin Viatris 600 mg and confirm the status directly with Viatris ApS, as DKMA advises.
  • The stated disruption window ends in mid-November 2026. Because the notice gives no further detail, teams should plan on the basis of company confirmation rather than assumptions.
  • Regulatory and quality teams should note that DKMA cites production problems as the cause but gives no further technical detail.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →